[Home ] [Archive]   [ فارسی ]  
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Indexing Databases::
Editorial Board::
Executive Members::
Instruction to Authors::
Peer Review::
Articles Archive::
Contact Us::
Site Facilities::
::
Search in website

Advanced Search
Receive site information
Enter your Email in the following box to receive the site news and information.
:: Search published articles ::
Showing 1 results for K562 Erthromyloidy Cancer Cell Line

M Vaezi , M Mohammadzadeh , Y Pazhang ,
Volume 19, Issue 3 (10-2017)
Abstract

Background and Objective: Lovastatin is a HMG-CoA reductase inhibitor and used for the treatment of hypercholesterolemia. Inhibition of HMG-CoA reductase results in inhibiting the activity of the Ras proto-oncogene that has mutations in most cancers. This study was done to determine the Anti-proliferative and apoptotic effects of Lovastatin on K562 Erthromyloidy cancer cell line.
Methods: The K562 Erthromyloidy cancer cell line were cultured and treated with different concentrations of lovastatin. Their antitumor effect on K562 cells were assessed via MTT assay after 72 hours. Hoechst (33342) staining and DNA electrophoresis were used for study of apoptosis.
Results: Lovastatin had antitumor effect on K562 Erthromyloidy cancer cell line and this effect increased by incease of time and concentration.The maximum inhibitory effect was 59% in higher concentration (100 µM) and 72 hours after the treatment. Reduced cell growth at 24 and 48 hours after treatment was 24% and 43%, respectively. Lovastatin significantly inhibited K562 cell growth (P<0.05).
Conclusion: This study showed that lovastatin has antitumor effect on K562 Erthromyloidy cancer cell line.

Page 1 from 1     

مجله دانشگاه علوم پزشکی گرگان Journal of Gorgan University of Medical Sciences
Persian site map - English site map - Created in 0.05 seconds with 23 queries by YEKTAWEB 4710
Creative Commons License
This work is licensed under a Creative Commons — Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)